Physicians in the Lymphoma Division at John Theurer Cancer Center, part of Hackensack University Medical Center in New Jersey, treat hundreds of lymphoma patients every year.

Our team has been at the forefront of the development of many novel therapies—particularly those for mantle cell lymphoma, diffuse large B-cell lymphoma, follicular lymphoma, T-cell lymphomas, Hodgkin lymphoma, and chronic lymphocytic leukemia (CLL). When you come to us for your care, you benefit from highly subspecialized comprehensive high-quality care based on the findings of the latest medical research, as well as opportunities to participate in clinical trials of promising new therapies.

Treatment Based on the Biology of Your Cancer

Progress in understanding the biology of lymphoma has shown that they differ greatly at the molecular level, even if they look the same under the microscope. This explains also why they behave differently (for example, whether or not they respond to chemotherapy). There are over 100 distinct subtypes of lymphoma, and it imperative to get an accurate diagnosis and molecular analysis of your cancer to ensure you receive the most effective therapy. Our hematopathologists are exceptional and essential for helping your doctor to understand precisely the molecular features—and therefore behavior—of your disease to customize the type of therapy that you need.

A Team of Experts for Every Type of Lymphoma

The scope and breadth of our program have enabled us to subspecialize in the care of people with lymphoid malignancies. In addition, we have assembled a dedicated team of pathologists, infectious disease specialists, lymphoma radiologists, and radiation oncologists who meet weekly to discuss the best course of care for each individual case. This allows every lymphoma patient to receive a personalized treatment plan that addresses his or her specific type of cancer.

Leaders in Bone Marrow Transplantation for Lymphoma

John Theurer Cancer Center has one of the largest stem cell transplantation programs in the country, including its use for lymphoma treatment, with over 1,500 stem cell transplantations performed since its inception. Through our relationship with the National Cancer Institute Immunology Branch, we have developed new approaches to prevent graft-versus-host disease after transplantation (a complication in which cells from the donor attack tissues of the recipient). We are currently the only center conducting a clinical trial of combined ipilimumab and nivolumab immunotherapy after transplantation to improve outcomes and reduce the risk of recurrence in patients with high-risk disease.

Partners in Lymphoma Education

John Theurer Cancer Center partners with the Lymphoma Research Foundation and Leukemia Lymphoma Society, among others, to promote education for both professionals and patients through grand rounds and other platforms. These initiatives demonstrate our commitment to sharing advances in lymphoma care with all healthcare providers, ultimately benefiting patients everywhere.

Our Lymphoma Specialists


A Robust Program of Lymphoma Clinical Trials

Our team has also set up a comprehensive clinical research group entirely focused on lymphoma and CLL, offering novel options including Phase I studies (when a drug is first evaluated in people) and novel combinations, as well as immunotherapy (which boosts the power of the immune system to find and kill cancer cells). Finally, through our extensive tumor banking facility (a repository storing tissue samples for research) and genomics program, we have identified new biomarkers to predict outcomes in lymphoma patients.

Thanks to our strong commitment to research, the Lymphoma Division has been able not only to offer new options to our patients when needed, but also to participate in progress and advancement of the field of lymphoma and CLL research. Using outcomes research data from COTA (Cancer Outcomes Tracking and Analysis, an initiative using “big data” to observe patterns of response to therapy), the Lymphoma Division is looking at the impact of the sequence of therapies and of co-morbidities (other illnesses a patient may have) when choosing the best option for a patient with lymphoma or CLL. Our research has been published in leading medical journals, including the New England Journal of Medicine, Lancet, Nature Medicine, Blood, and Journal of Clinical Oncology, among others, in addition to presentations at national and international conferences.